Penny stock picks gave the heads up on RPRX in June on Proellex lift, and now there could be a chance to make more money on this penny stock play with Androxal. And we have are adding this to our radar on FDA news for Androxal. RPRX : (Nasdaq) Are awaiting response from the FDA Division of Urologic and Reproductive products to move Androxal into Phase 3 studies for secondary hypogonadism, submitted response to FDA on 2/7/10 re 1. literature review on incidence of infertility associated with the use of exogenous testosterone and 2. revised Androxal label which better defines target population.

Pennystockspicksus has received no compensation for this feature, Pennystockspicksus have no position in RPRX.